Delayed release drug formulation
In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
1. A delayed release drug formulation for oral administration, said delayed release drug formulation comprising:
a core comprising a drug;
an isolation layer coating said core; and
an outer coating for providing colonic release of said drug, said outer coating comprising an outer layer and an inner layer,
wherein said outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 6.5 or above, and
wherein the inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being a polycarboxylic acid polymer that is at least partially neutralized, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions.
2. The delayed release drug formulation of claim 1 , wherein colonic release of said drug from said delayed release drug formulation is accelerated compared to an equivalent formulation without said isolation layer.
3. The delayed release drug formulation of claim 1 , wherein lag time in vitro in Krebs buffer at pH 7.4 after 2 h at 0.1M HCl is reduced by at least 10%.
4. The delayed release drug formulation of claim 1 , wherein lag time in vitro in Krebs buffer at pH 7.4 after 2 h at 0.1M HCl is reduced by at least 10 minutes.
5. The delayed release drug formulation of claim 1 , having a coating amount from about 1 mg polymer/cm 2 to about 5 mg polymer/cm 2 .
6. The delayed release drug formulation of claim 1 , having a thickness from about 5 μm to about 100 μm.
7. The delayed release drug formulation of claim 1 , wherein said isolation layer comprises at least one non-ionic polymer.
8. The delayed release drug formulation of claim 1 , wherein said isolation layer comprises at least one polymer selected from the group consisting of methylcellulose; hydroxypropyl cellulose; hydroxypropyl methylcellulose; poly(ethylene oxide)-graft-polyvinyl alcohol; polyvinylpyrollidone; and polyvinyl alcohol.
9. The delayed release drug formulation of claim 1 , wherein said isolation layer comprises hydroxypropyl methylcellulose.
10. The delayed release drug formulation of claim 1 , wherein said polycarboxylic acid polymer is fully neutralized.
11. A method of accelerating drug release in the intestine of a subject from a delayed release drug formulation for oral administration to said subject, the method comprising administering the delayed release drug formulation comprising:
an isolation layer between a core and an outer coating,
the core comprising a drug; and
the outer coating being suitable for providing intestinal release of said drug, and said outer coating comprising an outer layer and an inner layer,
wherein the outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above, and
wherein the inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being a polycarboxylic acid polymer that is at least partially neutralized, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions.
12. A method of producing a delayed release drug formulation for oral administration, said method comprising:
providing a core comprising a drug;
coating said core with an isolation layer to produce an isolated core; and
coating said isolated core with an outer coating for providing intestinal release of said drug, said outer coating comprising an outer layer and an inner layer,
wherein said delayed release drug formulation provides accelerated release of the drug in the intestine of the subject;
wherein the outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above, and
wherein the inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being a polycarboxylic acid polymer that is at least partially neutralized, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions.
13. A method, of
preventing deceleration of drug release in the intestine of a subject from a delayed release drug formulation for oral administration administering the delayed release drug formulation comprising:
a core comprising a drug;
an isolation layer coating said core; and
an outer coating for providing intestinal release of said drug, said outer coating comprising an outer layer and an inner layer,
wherein the outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above, and
wherein the inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being a polycarboxylic acid polymer that is at least partially neutralized, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions.
14. The method of claim 13 , wherein lag time in vitro in Krebs buffer at pH 7.4 after 2 h at 0.1M HCl is increased after storage by no more than 5%.
15. The method as claimed in claim 13 , wherein lag time in vitro in Krebs buffer at pH 7.4 after 2 h at 0.1M HCl is increased after storage by no more than 10 minutes.
16. The method of claim 13 , wherein said delayed release drug formulation is stored in a closed high density polyethylene container for at least 1 month at 40° C./75% RH.
17. The method of claim 13 , wherein said delayed release drug formulation is stored in a closed high density polyethylene container for at least 3 months at 25° C./60% RH.
18. The method of claim 13 , wherein said isolation layer comprises hydroxypropyl methylcellulose.
19. The method of claim 13 , wherein said outer layer comprises said pH dependently soluble polymeric material in admixture with a digestible polymeric material susceptible to attack by colonic bacteria.
20. The formulation of claim 1 , wherein said core is acidic.
21. The formulation of claim 1 , wherein said drug is an anti-inflammatory agent.
22. The formulation of claim 1 , wherein said drug is 5-aminosalicylic acid.
23. The formulation of claim 1 , wherein said polycarboxylic acid polymer is fully neutralized.
24. The formulation of claim 1 , wherein said pH dependently soluble polymeric material of said outer layer is based on the same polycarboxylic acid polymer as said soluble polymeric material of said inner layer, said soluble polymeric material of said inner layer having a higher degree of neutralization than said pH dependently soluble polymeric material of said outer layer.
25. The formulation of claim 1 , wherein said polycarboxylic acid polymer of said soluble polymeric material of said inner layer is selected from the group consisting of polymethacrylate; cellulose acetate phthalate; polyvinyl acetate phthalate; hydroxypropyl methylcellulose phthalate; hydroxypropyl methylcellulose acetate succinate; cellulose acetate trimellitate; xanthan gum; alginates; and shellac.
26. The formulation of claim 1 , wherein said soluble polymeric material of said inner layer is an at least partially neutralized co-polymer of (meth)acrylic acid and a (meth)acrylic acid C 1-4 alkyl ester.
27. The formulation of claim 1 , wherein said soluble polymeric material of said inner layer is a fully neutralized co-polymer of (meth)acrylic acid and (meth)acrylic acid methyl ester.
28. The formulation of claim 1 , wherein said inner layer further comprises at least one additive selected from the group consisting of a buffer agent and a base, wherein the buffer agent is an organic acid or an inorganic salt.
29. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and a base, wherein the buffer agent is an organic acid or an inorganic salt.
30. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is selected from the group consisting of a carboxylic acid having from 1 to 16 carbon atoms, an alkali metal salt, an alkali earth metal salt, an ammonium salt and a soluble metal salt.
31. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is a phosphate salt.
32. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is potassium dihydrogen phosphate.
33. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is present in the inner layer in a total amount from about 0.1 wt % to about 50 wt % based on a dry weight of the soluble polymeric material of the inner layer.
34. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is present in the inner layer in a total amount from about 0.1 wt % to about 20 wt % based on a dry weight of the at least partially neutralized polycarboxylic acid of the inner layer.
35. The formulation of claim 1 , wherein the inner layer further comprises a buffer agent and the buffer agent is present in the inner layer in a total amount from about 10 wt % to about 30 wt % based on a dry weight of the non-ionic polymer of the inner layer.
36. The formulation of claim 1 , wherein the inner layer further comprises a base and the base is selected from the group consisting of a hydroxide base, alkali metal bicarbonate, alkali metal carbonate, alkali metal phosphate, alkali metal citrate, or physiologically tolerated amine.
37. The formulation of claim 1 , wherein the inner layer further comprises a base and the base is a hydroxide base.
38. The formulation of claim 1 , wherein the inner layer further comprises a base and the base is sodium hydroxide.
39. The formulation of claim 1 , wherein the pH dependently soluble polymeric material of the outer layer is a blend of at least two different polymers having a pH threshold of about pH 6 and above.
40. The formulation of claim 39 , wherein the at least two different polymers in the blend are different polymethacrylate polymers.
41. The formulation of claim 39 , wherein there are the at least two different polymers in the blend in a ratio from about 40:60 to about 60:40.
42. The formulation of claim 1 , wherein said pH dependently soluble polymeric material is present in the outer layer as a sole film forming polymeric material.
43. The formulation of claim 1 , wherein said pH dependently soluble polymeric material is present in the outer layer in admixture with a digestible polymeric material which is susceptible to attack by colonic bacteria.
44. The formulation of claim 43 , wherein said digestible polymeric material and said pH dependently soluble polymeric material are present in the outer layer in a ratio of up to about 60:40.
45. The formulation of claim 43 , wherein said digestible polymeric material and said pH dependently soluble polymeric material are present in the outer layer in a ratio from about 25:75 to about 35:65.
46. The formulation of claim 43 , wherein said digestible polymeric material and said pH dependently soluble polymeric material are present in the outer layer in a ratio from about 40:60 to about 60:40.